% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Khoja:177465,
author = {L. Khoja and R. P. Weber and P. M. Webb and S. J. Jordan
and A. Muthukumar and J. Chang-Claude$^*$ and R. T.
Fortner$^*$ and A. Jensen and S. K. Kjaer and H. Risch and
J. A. Doherty and H. R. Harris and M. T. Goodman and F.
Modugno and K. Moysich and A. Berchuck and J. M. Schildkraut
and D. Cramer and K. L. Terry and H. Anton-Culver and A.
Ziogas and M. T. Phung and G. E. Hanley and A. H. Wu and B.
Mukherjee and K. McLean and K. Cho and M. C. Pike and C. L.
Pearce and A. W. Lee},
collaboration = {A. O. C. S. Group},
title = {{E}ndometriosis and menopausal hormone therapy impact the
hysterectomy-ovarian cancer association.},
journal = {Gynecologic oncology},
volume = {164},
number = {1},
issn = {0090-8258},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2021-02557},
pages = {195-201},
year = {2022},
note = {2022 Jan;164(1):195-201},
abstract = {To evaluate the association between hysterectomy and
ovarian cancer, and to understand how hormone therapy (HT)
use and endometriosis affect this association.We conducted a
pooled analysis of self-reported data from 11 case-control
studies in the Ovarian Cancer Association Consortium (OCAC).
Women with (n = 5350) and without ovarian cancer
(n = 7544) who never used HT or exclusively used either
estrogen-only therapy (ET) or estrogen+progestin therapy
(EPT) were included. Risk of invasive epithelial ovarian
cancer adjusted for duration of ET and EPT use and
stratified on history of endometriosis was determined using
odds ratios (ORs) with $95\%$ confidence intervals
(CIs).Overall and among women without endometriosis, there
was a positive association between ovarian cancer risk and
hysterectomy (OR = 1.19, $95\%$ CI 1.09-1.31 and
OR = 1.20, $95\%$ CI 1.09-1.32, respectively), but no
association upon adjusting for duration of ET and EPT use
(OR = 1.04, $95\%$ CI 0.94-1.16 and OR = 1.06, $95\%$ CI
0.95-1.18, respectively). Among women with a history of
endometriosis, there was a slight inverse association
between hysterectomy and ovarian cancer risk (OR = 0.93,
$95\%$ CI 0.69-1.26), but this association became stronger
and statistically significant after adjusting for duration
of ET and EPT use (OR = 0.69, $95\%$ CI 0.48-0.99).The
hysterectomy-ovarian cancer association is complex and
cannot be understood without considering duration of ET and
EPT use and history of endometriosis. Failure to take these
exposures into account in prior studies casts doubt on their
conclusions. Overall, hysterectomy is not risk-reducing for
ovarian cancer, however the inverse association among women
with endometriosis warrants further investigation.},
keywords = {Endometriosis (Other) / Hormone therapy (Other) /
Hysterectomy (Other) / Ovarian cancer (Other)},
cin = {C020},
ddc = {610},
cid = {I:(DE-He78)C020-20160331},
pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
pid = {G:(DE-HGF)POF4-313},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:34776242},
doi = {10.1016/j.ygyno.2021.10.088},
url = {https://inrepo02.dkfz.de/record/177465},
}